贝达药业：海外子公司Xcovery主导推进了恩沙替尼的全球多中心Ⅲ期临床研究

Group 1 - The company announced that its overseas subsidiary Xcovery is leading a global multicenter Phase III clinical study for Ensartinib, accumulating valuable experience [2] - The company has established a deep strategic partnership with He Yuan Bio, an important collaborator in the innovative ecosystem [2] - The company will provide strong support for the global clinical research of plant-derived recombinant human albumin [2]